Medication-Related Osteonecrosis of the Jaw—A Continuing Issue

Applied Sciences

Dariusz Chlubek¹  Maciej Sikora²  Krzysztof Wróbel²  Maria Jas³  Maciej Chęciński⁴ 

[1] Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland;Department of Maxillofacial Surgery, Hospital of the Ministry of Interior, Wojska Polskiego 51, 25-375 Kielce, Poland;Non-Public Healthcare Center for Dentistry, Maxillofacial Surgery and Implantology “Ars Medica”, Zagórska 20/15-16, 25-355 Kielce, Poland;Preventive Medicine Center, Komorowskiego 12, 30-106 Kraków, Poland;

关键词: osteonecrosis;    bisphosphonates;    angiogenesis inhibitors;    MRONJ;    BRONJ;   

DOI  :  10.3390/app11177781

来源: DOAJ

【 摘 要 】

Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a condition that is becoming more common in the everyday practice of both dental and maxillofacial surgeons. Materials and methods: This paper aims to provide a comprehensive and easy to read by clinicians presentation of comprehensive, accessible, and up-to-date data on MRONJ. The individual chapters focus on the etiology, epidemiology, diagnosis, prevention, treatment, and recurrence of MRONJ. Results and discussion: It has been observed over the years that among drugs that increase the risk of the disease, apart from bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies should also be included. A thorough physical and subjective examination, periodic correction of dental prostheses, and an adequate preparation for even the simplest of procedures in the oral cavity area can prevent or minimize the risk of MRONJ. Conclusions: It is extremely difficult to treat once it occurs and oftentimes is a recurring problem that leads to a multitude of symptoms that gradually decrease the quality of a patient’s life.

【 授权许可】

Unknown